EA201171091A1 - Улучшенные способы лечения мигрени на основе миметиков грелина - Google Patents

Улучшенные способы лечения мигрени на основе миметиков грелина

Info

Publication number
EA201171091A1
EA201171091A1 EA201171091A EA201171091A EA201171091A1 EA 201171091 A1 EA201171091 A1 EA 201171091A1 EA 201171091 A EA201171091 A EA 201171091A EA 201171091 A EA201171091 A EA 201171091A EA 201171091 A1 EA201171091 A1 EA 201171091A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mimetic
greeme
basis
treating migraine
improved ways
Prior art date
Application number
EA201171091A
Other languages
English (en)
Other versions
EA021055B1 (ru
Inventor
Уилльям Дж. Полвино
Original Assignee
ХЕЛСИНН ТЕРАПЬЮТИКС (Ю.Эс.), ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ХЕЛСИНН ТЕРАПЬЮТИКС (Ю.Эс.), ИНК. filed Critical ХЕЛСИНН ТЕРАПЬЮТИКС (Ю.Эс.), ИНК.
Publication of EA201171091A1 publication Critical patent/EA201171091A1/ru
Publication of EA021055B1 publication Critical patent/EA021055B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу усиления всасывания лекарственных средств против мигрени и, тем самым, лечения мигреней путем совместного введения индивидууму, нуждающемуся в этом, эффективного количества миметика грелина или его фармацевтически приемлемой соли, гидрата или сольвата и по меньшей мере одного лекарственного средства против мигрени, выбранного из агониста рецепторов серотонина 5-HT, производного триптамина, производного эрголина, нестероидного противовоспалительного средства или анальгетика или любой их комбинации.
EA201171091A 2009-02-27 2010-03-01 Способ увеличения скорости всасывания триптанов и способ лечения осложнений или симптомов мигрени EA021055B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15612909P 2009-02-27 2009-02-27
PCT/US2010/025725 WO2010099522A1 (en) 2009-02-27 2010-03-01 Enhanced migraine treatments based on ghrelin mimetics

Publications (2)

Publication Number Publication Date
EA201171091A1 true EA201171091A1 (ru) 2012-04-30
EA021055B1 EA021055B1 (ru) 2015-03-31

Family

ID=42144981

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171091A EA021055B1 (ru) 2009-02-27 2010-03-01 Способ увеличения скорости всасывания триптанов и способ лечения осложнений или симптомов мигрени

Country Status (17)

Country Link
US (2) US8486976B2 (ru)
EP (1) EP2400986B1 (ru)
JP (1) JP6041491B2 (ru)
KR (2) KR101707666B1 (ru)
CN (1) CN102333545B (ru)
AU (1) AU2010217792B2 (ru)
BR (1) BRPI1008698A2 (ru)
CA (1) CA2752813C (ru)
EA (1) EA021055B1 (ru)
ES (1) ES2558701T3 (ru)
IL (1) IL214443A0 (ru)
MX (1) MX2011008413A (ru)
NO (1) NO20111303A1 (ru)
SG (1) SG174158A1 (ru)
TW (1) TWI457331B (ru)
UA (1) UA105657C2 (ru)
WO (1) WO2010099522A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281701A1 (en) 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
WO2010144265A2 (en) * 2009-06-12 2010-12-16 Helsinn Therapeutics (U.S.), Inc. Ipamorelin diacetate injection and infusion solutions
WO2013095707A1 (en) * 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
US20220160815A1 (en) * 2019-05-31 2022-05-26 Lateral IP Pty Ltd Peptides and uses thereof
KR20220054244A (ko) * 2019-08-30 2022-05-02 헬신 헬스케어 에스아 개선된 안정성을 갖는 아나모렐린 정제의 제조 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
HUP9802580A3 (en) * 1995-12-22 1999-03-29 Novo Nordisk As Compounds with growth hormone releasing properties
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2348979A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (ru) * 1999-11-10 2005-08-15 Ново Нордіск А/С Соединение со свойствами освобождения гормона роста
EP1258250B1 (en) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
WO2005097261A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20100016363A1 (en) 2006-04-25 2010-01-21 Kowa Pharmaceuticals America, Inc. Fixed Combination Dosage Forms for the Treatment of Migraine
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法

Also Published As

Publication number Publication date
SG174158A1 (en) 2011-10-28
IL214443A0 (en) 2011-09-27
BRPI1008698A2 (pt) 2016-03-08
TWI457331B (zh) 2014-10-21
CN102333545A (zh) 2012-01-25
CN102333545B (zh) 2014-03-19
AU2010217792A1 (en) 2011-08-25
US20130289068A1 (en) 2013-10-31
NO20111303A1 (no) 2011-09-26
ES2558701T3 (es) 2016-02-08
AU2010217792B2 (en) 2015-10-22
MX2011008413A (es) 2011-09-22
CA2752813A1 (en) 2010-09-02
US8486976B2 (en) 2013-07-16
JP2012519184A (ja) 2012-08-23
EP2400986B1 (en) 2015-10-14
KR101707666B1 (ko) 2017-02-16
US8673947B2 (en) 2014-03-18
KR20110126155A (ko) 2011-11-22
UA105657C2 (ru) 2014-06-10
KR20160136473A (ko) 2016-11-29
WO2010099522A1 (en) 2010-09-02
US20100222388A1 (en) 2010-09-02
TW201035071A (en) 2010-10-01
EA021055B1 (ru) 2015-03-31
JP6041491B2 (ja) 2016-12-07
CA2752813C (en) 2017-03-28
EP2400986A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
EA201171091A1 (ru) Улучшенные способы лечения мигрени на основе миметиков грелина
MX2020000968A (es) Compuestos organicos.
MX2021014508A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2021013564A (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
MX2020000967A (es) Compuestos organicos.
PH12017502179A1 (en) Substituted heterocyclyl derivatives as cdk inhibitors
EA201992474A2 (ru) Агонисты 5ht для лечения нарушений
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
NZ715331A (en) Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
EA201690033A3 (ru) Морфинановые соединения
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
MX2012012277A (es) Compuestos organicos.
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
NO20085099L (no) Puritonderivativer som HM74A agonister
EA201190140A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
BR112017003570A2 (pt) tratamento de combinação de inibidores de sglt2 e agonistas de dopamina para prevenir distúrbios metabólicos em animais equinos
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2017010348A (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
EA202092036A1 (ru) Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
MX2020009928A (es) Compuestos organicos.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
EP3490554A4 (en) USES OF DOPAMINE BETA HYDROXYLASE (DBH) INHIBITORS AND SEROTONIN (5-HT) RECEPTOR ANTAGONISTS FOR CANCER TREATMENT
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine
EP2464355A4 (en) SUBSTITUTED TRIAZOLPHTHALAZINE DERIVATIVES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU